A clinical trial has found a COVID-19 vaccine in development at a Sinopharm subsidiary to be safe in children aged three to 17 years, according to Chinese state media.
COVID-19 vaccine developers initially focused their clinical trials on adults. Pfizer and Moderna went on to study their candidates in children after showing safety in adults, but even then those trials are only enrolling kids aged 12 years and up. In contrast, China National Biotec Group (CNBG), a subsidiary of Sinopharm, has data on the use of one of its vaccines in kids as young as three years.
Xinhua, China’s official state-run press agency, shared details of the study in an article. Summarizing the Xinhua article, Reuters reported the vaccine appears safe in children and shared a quote from CNBG Chairman Yang Xiaoming.
Xiaoming told Xinhua: “It should be noted that for three to five-year-old children, because their immune system is still developing, they must be carefully and closely monitored during vaccination.”…